Cargando…
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m(2)/day x7 days (n = 240) or conventional care reg...
Autores principales: | Döhner, Hartmut, Dolnik, Anna, Tang, Lin, Seymour, John F., Minden, Mark D., Stone, Richard M., del Castillo, Teresa Bernal, Al-Ali, Haifa Kathrin, Santini, Valeria, Vyas, Paresh, Beach, C. L., MacBeth, Kyle J., Skikne, Barry S., Songer, Steve, Tu, Nora, Bullinger, Lars, Dombret, Hervé |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286388/ https://www.ncbi.nlm.nih.gov/pubmed/30275526 http://dx.doi.org/10.1038/s41375-018-0257-z |
Ejemplares similares
-
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
por: Seymour, John F., et al.
Publicado: (2017) -
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023) -
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022) -
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
por: Roboz, Gail J., et al.
Publicado: (2021) -
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
por: Ravandi, Farhad, et al.
Publicado: (2021)